Clinical trials: Plasma Cell Tumor
Leukemia, Lymphoma
Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies
The purpose of this study is to find out how many irradiated natural killer (NK) cells can be safely given to patients with cancer that has recurred after an autologous stem cell transplant, and to see what effects (good and bad)…
- Conditions
- Leukemia, Lymphoma, Myeloma, Hodgkin's Disease
- Trial name
- NCT00990717
- Testing
- NK-92 cells
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Multiple Myeloma
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
This is a multi-center, open-label, Phase 1/2 study in China to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of CM336 in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT05299424
- Testing
- CM336_group 1, CM336_group 2a, CM336_group 2b
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Keymed Biosciences Co.Ltd
Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
This phase I trial is studying the side effects and best dose of giving tanespimycin together with bortezomib in treating patients with advanced solid tumors or lymphomas.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00096005
- Testing
- tanespimycin, bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia
Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00281983
- Testing
- alemtuzumab, anti-thymocyte globulin, filgrastim
- Where
- 13 sites in Canada, Germany
- Volunteers
- 100 people
- Sponsor
- German CLL Study Group
Multiple Myeloma
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
The purpose of this study is to determine the tolerated dose of pomalidomide and also to evaluate the pharmacokinetics, safety and efficacy of pomalidomide in patients with refractory or relapsed and refractory multiple myeloma.
- Trial name
- NCT01568294
- Testing
- pomalidomide
- Where
- 8 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Celgene
Osteoporosis, Multiple Myeloma
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in…
- Trial name
- NCT05775094
- Testing
- Romosozumab
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or…
- Trial name
- NCT04661137
- Testing
- Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Hackensack Meridian Health
Myeloma
Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients
Clinically demonstrated efficacy of Melphalan and Prednisone in MM subjects as well as the confirmed inhibitory effect of dasatinib on several tyrosine kinase receptors and pathways implicated in the pathophysiology of MM.
- Trial name
- D-MP (NCT01116128)
- Testing
- dasatinib, melphalan, prednisone
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione EMN Italy Onlus
Myeloma
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
One purpose of this study is to find out if a new combination of immune system treatments (MAGE-A3 vaccine plus activated T-cells) will allow the body to build up protection ("immunity") against the myeloma cells.
- Trial name
- NCT01245673
- Testing
- Prevnar- Pneumococcal Conjugate Vaccine (PCV), Activated/costimulated autologous T-cell, Revlamid® (Lenalidomide)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
This is a multicenter, open label clinical trial evaluating the safety of the combination of belantamab mafodotin + the combination treatment VRd (bortezomib, lenalidomide, dexamethasone) in newly diagnosed (ND) transplant…
- Trial name
- NCT04802356
- Testing
- Belantamab mafodotin, Bortezomib, Lenalidomide
- Where
- 12 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PETHEMA Foundation
Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma
Expanded Access to Venetoclax
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma
- Trial name
- NCT03123029
- Testing
- Venetoclax
- Sponsor
- AbbVie
Myeloma
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
The goal of this clinical research study is to learn if carfilzomib and vorinostat combined with gemcitabine, busulfan, and melphalan with a stem cell transplant will help to control multiple myeloma (MM).
- Trial name
- NCT02114502
- Testing
- Carfilzomib, SAHA, Gemcitabine
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
The purpose of this study is to study taste disturbances on patients with myeloma who received high dose melphalan.
- Trial name
- NCT03276481
- Testing
- Oral microbiota assessment, Comprehensive chemical gustometry, Measurement of salivary flow
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
Define maximum tolerable dose of the combination lenalidomide, bendamustine, prednisone.
- Trial name
- NCT01002703
- Testing
- Lenalidomide, Bendamustine, Prednisone
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Leipzig
Multiple Myeloma
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
This study is a multi-center, single-arm clinical study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic characteristics of CT103A as the first-line treatment in newly diagnosed high-risk multiple myeloma…
- Trial name
- NCT05181501
- Testing
- Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
- Where
- 4 sites in China
- Volunteers
- 20 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Multiple Myeloma
A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma
Multiple myeloma is a disease that resides primarily in the bone and has shown to be sensitive to radiation. Administration of a radiotherapy agent that targets the bone, such as Holmium-166-DOTMP, in conjunction with melphalan…
- Trial name
- NCT00039754
- Testing
- Holmium-166-DOTMP
- Sponsor
- Poniard Pharmaceuticals
Myeloma
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
Trial objectives: To decide whether the addition of nelfinavir to the approved antimyeloma therapy with bortezomib and dexamethasone has sufficient activity in proteasome inhibitor-resistant myeloma patients to merit further…
- Trial name
- NCT02188537
- Testing
- Nelfinavir, bortezomib, Dexamethasone
- Where
- 12 sites in Switzerland
- Volunteers
- 34 people
- Sponsor
- Swiss Cancer Institute
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial is studying the side effects and best dose of gossypol when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00891072
- Testing
- R-(-)-gossypol acetic acid, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Sunitinib in Treating Patients With Relapsed Multiple Myeloma
This phase II trial is studying how well sunitinib works in treating patients with relapsed multiple myeloma. Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking…
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00514137
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.